GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for slowing Alzheimer’s — a disease with few treatment options.

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) ...